Last Pa. Reglan Preemption Challenge Denied By High Court

Law360, Philadelphia (May 18, 2015, 4:37 PM EDT) -- The U.S. Supreme Court on Monday denied the last of three petitions seeking review of a Pennsylvania ruling that thousands of generic Reglan users’ state court product liability claims weren't necessarily preempted by federal law.

The decision marks the end of the line for several drugmakers in their effort to knock out roughly 2,300 coordinated suits in Philadelphia County Court of Common Pleas that claimed that generic versions of the digestion drug caused neurological damage.

Teva Pharmaceuticals USA Inc., Pliva Inc., Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC all had pushed the high court to step in to address a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS